These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22958482)

  • 1. Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.
    Bergmann-Leitner ES; Duncan EH; Mease RM; Angov E
    Malar J; 2012 Sep; 11():315. PubMed ID: 22958482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
    Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
    J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
    Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda.
    Apio B; Nalunkuma A; Okello D; Riley E; Egwang TG
    East Afr Med J; 2000 Apr; 77(4):189-93. PubMed ID: 12858901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
    Darko CA; Angov E; Collins WE; Bergmann-Leitner ES; Girouard AS; Hitt SL; McBride JS; Diggs CL; Holder AA; Long CA; Barnwell JW; Lyon JA
    Infect Immun; 2005 Jan; 73(1):287-97. PubMed ID: 15618165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.
    Spring MD; Chelimo K; Tisch DJ; Sumba PO; Rochford R; Long CA; Kazura JW; Moormann AM
    Infect Immun; 2010 Oct; 78(10):4431-41. PubMed ID: 20696832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
    Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
    Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.
    Reed ZH; Kieny MP; Engers H; Friede M; Chang S; Longacre S; Malhotra P; Pan W; Long C
    Vaccine; 2009 Mar; 27(10):1651-60. PubMed ID: 19038302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
    Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
    Singh B; Cabrera-Mora M; Jiang J; Galinski M; Moreno A
    Vaccine; 2010 Mar; 28(14):2580-92. PubMed ID: 20097151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
    Matsumoto S; Yukitake H; Kanbara H; Yamada T
    J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
    Hui G; Hashimoto C
    Vaccine; 2007 Jan; 25(5):948-56. PubMed ID: 17023096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.